Trial Profile
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil in Healthy Subjects Aged 9 to 13 Years in Malaysia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2021
Price :
$35
*
At a glance
- Drugs CYD TDV (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Dengue; Human papillomavirus infections
- Focus Pharmacodynamics
- Sponsors Sanofi Pasteur
- 01 Aug 2021 Results published in the Pediatric Infectious Disease Journal
- 21 May 2020 Status changed from active, no longer recruiting to completed.
- 24 Jun 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jul 2019.